[Hepatobiliary disease in cystic fibrosis].
Pérez-Aguilar
F
F
Servicio de Medicina Digestiva, Hospital La Fe, Valencia.
Berenguer Lapuerta
J
J
D001649:Bile Duct Diseases / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D015415:Biomarkers; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications* / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008107:Liver Diseases / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D015415:Biomarkers; C505032:CFTR protein, human; D002756:Cholagogues and Choleretics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D014580:Ursodeoxycholic Acid